Mergers & Acquisitions ·
On July 6, 2026, Tarsus Pharmaceuticals, Inc. acquired iRenix Medical, Inc. through a merger
TARSTarsus Pharmaceuticals, Inc.
On July 6, 2026, Tarsus Pharmaceuticals, Inc. acquired iRenix Medical, Inc. through a merger. The up-front consideration consisted of $37.5 million in cash and 607,093 shares of Tarsus common stock. Additionally, iRenix equityholders are eligible for milestone payments up to $490 million based on regulatory and commercial achievements, as well as revenue sharing payments in the low-to-mid single digits of future net sales for specific products. Tarsus operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutic products.